Literature DB >> 3107939

Discovery and partial characterization of primate motor-system toxins.

P S Spencer, J Hugon, A Ludolph, P B Nunn, S M Ross, D N Roy, H H Schaumburg.   

Abstract

beta-N-Oxalylamino-L-alanine (BOAA) and beta-N-methylamino-L-alanine (BMAA) are chemically related excitant amino acids isolated from the seed of Lathyrus sativus (BOAA) and Cycas circinalis (BMAA), consumption of which has been linked to lathyrism (an upper motor neuron disorder) and Guam amyotrophic lateral sclerosis (ALS), respectively. Both diseases are associated with degeneration of motor neurons. Experimentally, single doses of BOAA or BMAA induce seizures in neonatal mice and postsynaptic neuronal oedema and degeneration in explants of mouse spinal cord and frontal cortex. Preliminary studies show that these behavioural and pathological effects are differentially blocked by glutamate-receptor antagonists. In macaques, several weeks of daily oral doses of BOAA produce clinical and electrophysiological signs of corticospinal dysfunction identical to those seen in comparably well-nourished animals receiving a fortified diet based on seed of Lathyrus sativus. By contrast, comparable oral dosing with BMAA precipitates tremor and weakness, bradykinesia and behavioural changes, with conduction deficits in the principal motor pathway. BOAA and BMAA (or a metabolite thereof) are the first members of the excitotoxin family to have been shown to possess chronic motor-system toxic potential. These observations provide a rational basis for searching for comparable endogenous neurotoxins in sporadic and inherited forms of human motor neuron disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107939     DOI: 10.1002/9780470513422.ch14

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  15 in total

1.  Assessing the Combined Toxicity of BMAA and Its Isomers 2,4-DAB and AEG In Vitro Using Human Neuroblastoma Cells.

Authors:  Brendan J Main; Kenneth J Rodgers
Journal:  Neurotox Res       Date:  2017-06-20       Impact factor: 3.911

Review 2.  The Potential Role of BMAA in Neurodegeneration.

Authors:  Tracie Caller; Patricia Henegan; Elijah Stommel
Journal:  Neurotox Res       Date:  2017-06-13       Impact factor: 3.911

Review 3.  Interrelationships of undernutrition and neurotoxicity: food for thought and research attention.

Authors:  Peter S Spencer; Valerie S Palmer
Journal:  Neurotoxicology       Date:  2012-02-28       Impact factor: 4.294

Review 4.  MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis.

Authors:  Frank Cloutier; Alier Marrero; Colleen O'Connell; Pier Morin
Journal:  J Mol Neurosci       Date:  2014-11-30       Impact factor: 3.444

Review 5.  Cyanobacterial Neurotoxins: Their Occurrence and Mechanisms of Toxicity.

Authors:  Kenneth J Rodgers; Brendan J Main; Kate Samardzic
Journal:  Neurotox Res       Date:  2017-06-05       Impact factor: 3.911

6.  Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro.

Authors:  S G Carriedo; H Z Yin; J H Weiss
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

7.  BMAA extraction of cyanobacteria samples: which method to choose?

Authors:  Sandra Lage; Alfred Burian; Ulla Rasmussen; Pedro Reis Costa; Heléne Annadotter; Anna Godhe; Sara Rydberg
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-26       Impact factor: 4.223

Review 8.  The cyanobacteria derived toxin Beta-N-methylamino-L-alanine and amyotrophic lateral sclerosis.

Authors:  Sandra Anne Banack; Tracie A Caller; Elijah W Stommel
Journal:  Toxins (Basel)       Date:  2010-12-20       Impact factor: 4.546

9.  β-Methylamino-L-alanine-induced protein aggregation in vitro and protection by L-serine.

Authors:  Adam W Quinn; Connor R Phillips; Jake P Violi; Joel R Steele; Michael S Johnson; Mika T Westerhausen; Kenneth J Rodgers
Journal:  Amino Acids       Date:  2021-07-20       Impact factor: 3.520

10.  New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment.

Authors:  R Andrew Tasker; Amber L Adams-Marriott; Christopher A Shaw
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.